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Association of Infectious Disease Physician Approval of Peripherally Inserted
Central Catheter With Appropriateness and Complications
Valerie M. Vaughn, MD, MSc; Megan O’Malley, PhD; Scott A. Flanders, MD; Tejal N. Gandhi, MD; Lindsay A. Petty, MD; Anurag N. Malani, MD; Allison Weinmann, MBBS;
Jennifer K. Horowitz, MA; Vineet Chopra, MD, MSc

Abstract
IMPORTANCE Peripherally inserted central catheters (PICCs) are frequently used to deliver
intravenous antimicrobial therapy. However, inappropriate PICC use may lead to patient harm.
OBJECTIVE To evaluate whether infectious disease physician approval prior to PICC placement for
intravenous antimicrobials is associated with more appropriate device use and fewer complications.

Key Points
Question Is approval by an infectious
disease physician prior to placement of a
peripherally inserted central catheter
(PICC) for intravenous antimicrobials
associated with appropriate device use
or complications?

DESIGN, SETTING, AND PARTICIPANTS This cohort study of 21 653 PICCs placed for a primary

Findings In this cohort study of 21 653

indication of intravenous antimicrobial therapy between January 1, 2015, and July 26, 2019, was

PICCs placed for intravenous

conducted in 42 hospitals participating in a quality collaborative across Michigan among hospitalized

antimicrobials in 42 hospitals, 47% of

medical patients.

PICCs were placed with approval of an
infectious disease physician. Compared

MAIN OUTCOMES AND MEASURES Appropriateness of PICCs was defined according to the

with nonapproved PICCs, approved

Michigan Appropriateness Guide for Intravenous Catheters as a composite measure of (1) single-

PICCs were more likely to be

lumen catheter use, (2) avoiding use of PICCs for 5 days or less, and (3) avoiding use of PICCs for

appropriately placed, and the patients

patients with chronic kidney disease (defined as an estimated glomerular filtration rate <45 mL/min/

less likely to experience complications.

2

1.73 m ). Complications related to PICCs included catheter occlusion, deep vein thrombosis, and
central line–associated bloodstream infection. The association between infectious disease physician
approval, device appropriateness, and catheter complications was assessed using multivariable
models, adjusted for patient comorbidities and hospital clustering. Results were expressed as odds
ratios with 95% CIs.

Meaning This cohort study suggests
that infectious disease physician
approval of PICCs prior to placement for
intravenous antimicrobial therapy is
associated with more appropriate
device use and fewer complications.

RESULTS A total of 21 653 PICCs were placed for intravenous antimicrobials (11 960 PICCs were
placed in men [55.2%]; median age, 64.5 years [interquartile range, 53.4-75.4 years]); 10 238 PICCs
(47.3%) were approved by an infectious disease physician prior to placement. Compared with PICCs
with no documented approval, PICCs with approval by an infectious disease physician were more
likely to be appropriately used (72.7% [7446 of 10 238] appropriate with approval vs 45.4% [5180 of

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

11 415] appropriate without approval; odds ratio, 3.53; 95% CI, 3.29-3.79; P < .001). Furthermore,
approval was associated with lower odds of a PICC-related complication (6.5% [665 of 10 238] with
approval vs 11.3% [1292 of 11 415] without approval; odds ratio, 0.55; 95% CI, 0.50-0.61).
CONCLUSIONS AND RELEVANCE This cohort study suggests that, when PICCs were placed for
intravenous antimicrobial therapy, infectious disease physician approval of PICC insertion was
associated with more appropriate device use and fewer complications. Policies aimed at ensuring
infectious disease physician approval prior to PICC placement for antimicrobials may improve
patient safety.
JAMA Network Open. 2020;3(10):e2017659. doi:10.1001/jamanetworkopen.2020.17659
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Introduction
Peripherally inserted central catheters (PICCs) are central venous catheters used ubiquitously in
medical care. Compared with central venous catheters placed in the neck or chest, PICCs are placed
in upper-extremity veins in adults and consequently avoid many of the immediate insertion
complications associated with device placement. As PICC use has increased, however, reports of
complications, such as deep vein thrombosis (DVT) and central line–associated bloodstream
infection (CLABSI), have emerged.1 One strategy to reduce the risk of PICC-related complications is
to consider the appropriateness of PICC use, including aspects such as device characteristics and use
of alternatives. For example, use of single-lumen (vs multilumen) devices can reduce the risk of DVT
or CLABSI.2,3 Similarly, use of PICCs with a smaller cross-sectional diameter (ie, catheter gauge) is
known to be associated with fewer thrombotic complications.4 Furthermore, because safer
alternative devices are available,5 PICC use should be avoided if access is needed for a brief period (ie,
ⱕ5 days) or for patients with chronic kidney disease.6,7 Collectively, these findings have led to
Choosing Wisely recommendations8 and appropriateness criteria9 to inform and benchmark
PICC use.
One of the most common indications for PICC insertion is intravenous antimicrobial therapy.
Consequently, infectious disease (ID) physicians are often involved in decision-making related to
PICC use. If they are consulted early, ID physicians may be able to prevent inappropriate PICC use—for
example, for patients who could have their antimicrobials discontinued or switched to oral therapy.
Similarly, because ID physicians often treat CLABSIs, they may be more likely to recommend
interventions to reduce the risk of CLABSI, such as the use of single-lumen PICCs or antimicrobial
catheters in patients who are at high risk of adverse events.10 Despite this, little is known about the
association of ID physician approval with PICC appropriateness and outcomes. Because device
complications are common in patients receiving intravenous antimicrobials,11 there may be an
opportunity to improve patient safety by engaging ID physicians prior to PICC insertion.
The Michigan Hospital Medicine Safety Consortium (HMS) is a statewide quality collaborative
aimed at preventing adverse events in hospitalized medical patients. Since 2015, the HMS has
collected detailed data on PICCs, allowing for assessment of PICC appropriateness, and patient
outcomes. We sought to evaluate whether ID physician approval of PICC use prior to placement for
intravenous antimicrobials is associated with appropriate device use and fewer complications.

Methods
Study Setting and Participants
This prospective cohort study included patients who had a PICC inserted between January 1, 2015,
and July 26, 2019, in 42 diverse Michigan hospitals participating in the HMS (a collaborative quality
initiative funded by Blue Cross Blue Shield of Michigan). Hospital participation in the HMS is
voluntary and includes almost half of all nongovernment hospitals in Michigan, including rural
hospitals, community hospitals, and academic teaching hospitals.12 Sampling, inclusion, and
exclusion criteria have been described previously.6,13 In brief, the HMS collects data on adult medical
patients admitted to a general ward or an intensive care unit within a participating hospital who had
a PICC placed for any reason during the course of clinical care. Patients are excluded if they are
younger than 18 years, pregnant, admitted to a nonmedical service (ie, surgery), or admitted for
observation. Data from patients are sampled at each facility in 2-week intervals, with 17 medical
(intensive or general care) patients who received PICCs included in each wave at each hospital. This
study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guidelines. Because the purpose of the HMS is to measure and improve the quality of existing
practice, this project received a “not-regulated” status from the University of Michigan Institutional
Review Board; all patient data were deidentified.
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For this analysis, we were specifically interested in patients for whom the primary indication for
PICC insertion was documented as intravenous antimicrobial therapy. Thus, PICCs were included only
if they had an indication for intravenous antimicrobials documented in the physician order, vascular
access insertion note, or interventional radiology procedure note. Peripherally inserted central
catheters for which the primary indication included other reasons (eg, difficult access or
chemotherapy) were excluded.

Data Collection
Trained data abstractors at each hospital collected detailed information from medical records using a
standardized template including patient data, clinician data (eg, indication for insertion or
consultants), and device characteristics (eg, number of lumens). Hospitals undergo random quality
assurance checks to verify accuracy. In addition, data on PICC complications, including catheter
occlusion, symptomatic DVT, and CLABSI, were recorded using standardized definitions14 and
confirmed by medical record review. After PICC placement, all patients were followed up
prospectively until PICC removal, 30 days, or death.

Outcomes
The primary outcome of interest was the appropriateness of PICC use, assessed based on the
Michigan Appropriateness Guide for Intravenous Catheters.9 Accordingly, each PICC placement for
antimicrobial therapy was evaluated according to the following 3 appropriateness metrics: (1) use of
single-lumen rather than multilumen catheters, (2) use of PICCs for more than 5 days (as opposed
to ⱕ5 days), and (3) avoiding PICC use in patients with chronic kidney disease (CKD; estimated
glomerular filtration rate <45 mL/min/1.73 m2). Therefore, PICCs were considered fully appropriate if
the device was single-lumen, in place for more than 5 days, and inserted in a patient without CKD.
Peripherally inserted central catheters that did not meet 1 or more of these criteria were considered
inappropriate.
In addition to catheter appropriateness, we assessed major complications associated with PICC
use, including CLABSI, venous thromboembolism, and catheter occlusion. A PICC-related
bloodstream infection (ie, CLABSI) was defined in accordance with the Centers for Disease Control
and Prevention and National Healthcare Safety Network criteria.15,16 Venous thromboembolism was
defined as clinically diagnosed upper-extremity DVT and/or pulmonary embolism in a symptomatic
patient that was confirmed via imaging (ultrasonography or venograpahy for DVT and computed
tomography, ventilation perfusion scan, or pulmonary angiography for pulmonary embolism).13
Peripherally inserted central catheter occlusion was defined as a temporary or permanent inability to
aspirate blood or infuse therapeutic agents, necessitating use of tissue plasminogen activator.17 To
ensure reliability and integrity of definitions, all documented complications were manually audited.

Variables
We were primarily interested in whether ID physician approval of PICCs was associated with more
appropriate catheter use and fewer complications from PICC insertion for intravenous antimicrobials.
We ascertained ID physician approval of PICC use by examining consultation or primary notes for
specific verbiage supporting PICC insertion (eg, “OK to place PICC per ID”). To further explore
variation in ID physician approval, we also gathered information from participating hospitals on
whether ID physician consultation was available onsite or whether access to ID physicians occurred
via remote consulting. Finally, we also evaluated general hospital characteristics (eg, bed size),
sourcing data from an annual quality survey filled out by a physician or quality champion and data
abstractor at each participating hospital.

Statistical Analysis
We compared PICC appropriateness and complications by ID physician approval by fitting logistic
mixed-effect models with hospital-specific random effects after adjusting for patient characteristics
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(age, sex, body mass index, race/ethnicity, and Charlson Comorbidity Index score), hospital
characteristics (number of beds, profit status, and teaching status), and year of PICC placement.
There were minimal missing data, and we had outcome data on all but 3 patients (4958 had 14-day
but not 30-day follow-up information). Results were expressed as raw proportions and unadjusted or
adjusted odds ratios (ORs) with 95% CIs. To ensure rigor and to take into account inflation that may
occur when the incidence of events was low, unadjusted and adjusted relative risk ratios with 95%
CIs were also estimated. All pairwise comparisons were made using t tests for continuous data and χ2
tests for categorical data. To explore hospital variability, we also report the percentage of PICCs that
were approved by ID physicians with 95% CIs (after excluding hospitals with <25 PICCs). For the
primary analysis, we conducted sensitivity analyses in which we (1) report risk ratios and (2) included
only the first PICC placed per patient (removing 1126 PICCs placed in previously included patients).
All P values were from 2-sided tests, and results were deemed statistically significant at P < .05.

Results
Of 39 163 PICCs placed across HMS hospitals between January 1, 2015, and July 26, 2019, 21 653
(55.3%) had a primary indication of intravenous antimicrobials and were included in this analysis
(Figure 1). Included patients were predominantly White (16 451 PICCs [76.0%] placed in White
patients) and male (11 960 PICCs [55.2%] placed in men), with a median age of 64.5 years
(interquartile range, 53.4-75.4 years) (Table 1). Of the 21 653 included PICCs, 17 904 (82.7%) had
antimicrobials as the only indication for placement. Of the 21 653 PICCs with an indication for
intravenous antimicrobials, 15 172 (70.1%) were placed after a consultation with an ID physician; 6481
(29.9%) were not. Of the 15 172 PICCs placed after a consultation with an ID physician, documented
approval by the ID physician for PICC insertion was noted for 10 238 patients (67.5%). Thus, of the
21 653 PICCs placed for intravenous antimicrobials, 10 238 (47.3%) had approval from an ID physician
documented prior to device placement. The patient and PICC characteristics of patients with vs
without ID physician approval are shown in Table 1. Peripherally inserted central catheters placed
outside of the intensive care unit, that had antimicrobials as the only indication, or with a longer
catheter dwell time were more likely to have documented ID physician approval. Consultations with
ID physicians took place a mean of 1.5 days prior to PICC placement, and PICCs were placed a mean
of 5.6 days (median, 3 days) prior to hospital discharge.
All 42 hospitals had an antimicrobial stewardship program. Nearly three-quarters (73.8% [31 of
42]) of hospitals reported having onsite ID physicians, and 21.4% (9 of 42) had ID physicians who

Figure 1. Patient Inclusion Flow Diagram
39 163 Total PICCs

17 510 Excluded
Not placed for IV antibiotics

21 653 Placed for IV antibiotics

15 172 Consultation with ID
physician before placement

6481 No consultation with
ID physician

11 415 PICCs without documented
ID physician approval before
PICC insertion

10 238 Documented ID physician
approval before PICC
insertion
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either physically visited the hospital or were available for remote consulting. Approval rates by an ID
physician of PICCs placed with an indication for intravenous antimicrobials varied across hospitals
from 1.8% (7 of 393) to 90.7% (388 of 428), including among those without onsite ID physicians
(Figure 2). Hospital characteristics associated with ID physician approval are shown in Table 1.
Among PICCs with an indication for intravenous antimicrobials, those with ID physician approval
were more likely to be single-lumen (87.0% [8908 of 10 238] vs 59.7% [6820 of 11 415]; P < .001),
in place for more than 5 days (95.4% [9765 of 10 238] vs 85.8% [9792 of 11 415]; P < .001), and
placed in patients without CKD (87.1% [8914 of 10 238] vs 83.3% [9503 of 11 415]; P < .001) (Table 2).
Compared with PICCs without documented ID physician approval, those approved by an ID physician
were more likely to meet all 3 appropriateness criteria (72.7% [7446 of 10 238] appropriate with
approval vs 45.4% [5180 of 11 415] appropriate without approval). After adjustments, documented
ID physician approval remained associated with overall appropriateness (OR, 3.53; 95% CI,
3.29-3.79) and each individual metric of PICC appropriateness.
In unadjusted analyses, documented ID physician approval prior to insertion was associated
with lower odds of PICC-related complications (6.5% [665 of 10 238] with approval vs 11.3% [1292 of
11 415] without approval; OR, 0.55; 95% CI, 0.50-0.61; P < .001) (Table 2). Approval by an ID
physician was associated with fewer of 2 major complications, catheter occlusion (OR, 0.48; 95% CI,
0.43-0.54; P < .001) and DVT (OR, 0.68; 95% CI, 0.55-0.83; P < .001). Owing to low rates of CLABSI,

Table 1. Characteristics of PICCs With or Without ID Physician Approval
PICCs, No. (%)
Characteristic

With approval
(n = 10 238)

Without approval
(n = 11 415)

P value

Patient characteristics
Race/ethnicity
White

8127 (79.4)

8324 (72.9)

<.001

Black

1597 (15.6)

2478 (21.7)

<.001

Asian

61 (0.6)

63 (0.6)

.67

Other

184 (1.8)

222 (1.9)

.42

Unknown

163 (1.6)

189 (1.7)

.71

Male

5856 (57.2)

6104 (53.5)

Female

4382 (42.8)

5311 (46.5)

<.001

Age, median (IQR), y

64.5 (53.4-75.3)

64.6 (53.4-75.5)

.23

Charlson Comorbidity Index, median (IQR)

3 (1-5)

3 (1-5)

<.001

eGFR ≥45 mL/min/1.73 m2

1230 (12.0)

1755 (15.4)

<.001

In intensive care unit at the time of PICC insertion

345 (3.4)

2360 (20.7)

<.001

Antimicrobial is only indication

9411 (91.9)

8493 (74.4)

<.001

Multiple indications for PICC placement

827 (8.1)

2922 (25.6)

<.001

Single-lumen device

8908 (87.0)

6820 (59.7)

<.001

Dwell time, median (IQR), d

20 (12-34)

13 (7-25)

<.001

310 (217-458)

383 (255-573)

<.001

For profit

561 (5.5)

800 (7.0)

<.001

Nonprofit

9007 (88.0)

9621 (84.3)

<.001

5394 (52.7)

6868 (60.2)

<.001

7691/8834 (87.1)

8719/10 501 (83.0)

<.001

Sex

PICC characteristics

Hospital characteristics
Number of beds, median (IQR)
Hospital profit type

Academic hospital
ID physician consultation availabilitya
On site
Visiting or available for remote consultation

955/8834 (10.8)

1479/10 501 (14.1)

<.001

Unavailable

188/8834 (2.1)

303/10 501 (2.9)

<.001
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no difference in the odds of CLABSI was observed between groups (OR, 0.91; 95% CI, 0.71-1.16).
Results were similar after adjustment.
At the facility level, hospitals in the highest quartile of ID physician approval rates for PICC
placement demonstrated a higher overall level of PICC appropriateness (63.4% [3617 of 5709] vs
56.5% [9009 of 15 944]; P < .001) and lower complications (7.6% [433 of 5709] vs 9.6% [1524 of
15 944]; P < .001) than hospitals in the lower 3 quartiles of ID physician approval.
The association of ID physician approval with appropriateness and outcomes was robust to
multiple sensitivity analyses, including models reporting results as relative risks rather than as ORs
(eTable 1 in the Supplement) and models that were restricted to a single PICC placement in instances
where patients received multiple devices (eTable 2 in the Supplement).

Discussion
In this study of 21 653 PICCs placed for an indication for intravenous antimicrobials in 42 Michigan
hospitals, documented ID physician approval of PICC placement prior to insertion was associated
with a higher level of catheter appropriateness and fewer adverse events. Peripherally inserted
central catheters approved by ID physicians were more often single-lumen catheters, placed in

Figure 2. Proportion of Peripherally Inserted Central Catheters (PICCs) Placed for Intravenous Antimicrobials That Had Approval From an Infectious Disease (ID)
Physician Prior to Placement, by Hospital (N = 21 317)

PICCs with ID physician approval, %

120
Hospitals with on-site ID physician
100
Hospitals without on-site ID physician
80

60

40

20

0
Hospitals

Each bar represents 1 hospital. Not shown are 2 hospitals with less than 25 observations. Two hospitals also had no ID physician approvals (both lacked onsite ID physician availability).
Error bars indicate 95% CIs.

Table 2. Data on PICC Appropriateness and Complications by ID Physician Approval
Documented ID physician approval before PICC
insertion, No. (%)
Yes (n = 10 238)

No (n = 11 415)

Unadjusted OR (95% CI)

P value

Adjusted OR (95% CI)a

P value

7446 (72.7)

5180 (45.4)

3.18 (3.01-3.70)

<.001

3.53 (3.29-3.79)

<.001

Single lumen

8908 (87.0)

6820 (59.7)

4.40 (4.12-4.71)

<.001

5.20 (4.78-5.66)

<.001

Used in eGFR ≥45 mL/min/1.73 m2

8914 (87.1)

9503 (83.3)

1.36 (1.27-1.47)

<.001

1.24 (1.13-1.36)

<.001

In place for >5 d

9765 (95.4)

9792 (85.8)

3.41 (3.07-3.79)

<.001

3.50 (3.11-3.94)

<.001

665 (6.5)

1292 (11.3)

0.55 (0.50-0.61)

<.001

0.58 (0.52-0.65)

<.001

Catheter occlusion

432 (4.2)

976 (8.6)

0.48 (0.43-0.54)

<.001

0.51 (0.44-0.58)

<.001

DVT

148 (1.4)

238 (2.1)

0.68 (0.55-0.83)

<.001

0.72 (0.57-0.91)

.005

CLABSI

107 (1.0)

129 (1.1)

0.91 (0.71-1.16)

.43

0.96 (0.72-1.27)

.76

Outcomes
All 3 appropriateness criteria met

Major complication

b

Abbreviations: CLABSI, central line–associated bloodstream infection; DVT, deep vein
thrombosis; eGFR, estimated glomerular filtration rate; ID, infectious disease; OR, odds
ratio; PICC, peripherally inserted central catheter.
a

Adjusted results were calculated using a logistic mixed-effect model that adjusts for
patient age, sex, body mass index, race/ethnicity, Charlson Comorbidity Index score,

hospital bed number, profit status, teaching status, and year of PICC placement, with
hospital-specific random effects.
b

Full compliance with PICC recommendations indicates PICC device was single-lumen,
was not inserted if patient’s eGFR was less than 45 mL/min/1.73 m2, and was not in
place for 5 days or less.
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patients with normal kidney function, and with longer dwell times, suggesting that decision-making
related to these devices was purposeful and deliberate. Taken together, these findings have
important clinical and policy implications for the use and safety of PICCs placed for intravenous
antimicrobials.
Although our study was not designed to address how ID physician involvement prior to PICC use
may lead to differences in appropriateness and outcomes, 2 theories are plausible. First, it is possible
that ID physicians (who routinely see patients receiving outpatient parenteral antimicrobial therapy)
are more cognizant of device appropriateness; patients with PICCs approved by ID physicians were
more likely to have single-lumen devices and less likely to have CKD. The higher use of single-lumen
devices likely played a role in the association of ID physician approval with patient outcomes because
single-lumen devices have lower rates of occlusion, DVT, and CLABSI.18,19 Second, it is possible that
consulting ID physicians after PICC placement promulgates short-term PICC use. For example, if an ID
physician finds that intravenous antimicrobials are unnecessary, that the risk of complications is high,
or that oral therapy is appropriate, the ID physician may recommend removal of PICCs, leading to
dwell time of 5 days or fewer.20 In contrast, obtaining ID physician approval prior to PICC placement
may prevent PICC placement altogether. Because we track only patients for whom PICCs are placed
and not those for whom this decision may be different, a prospective intervention would be
necessary to test this hypothesis.
We found wide variation in the prevalence of ID physician approval prior to PICC placement.
Some of this difference may be associated with the varying availability of consultations. For example,
one hospital reported no access to ID physicians, and thus no approval by an ID physician prior to
PICC insertion was granted. However, among the 73.8% of hospitals with access to onsite ID
physicians, approval prior to PICC use varied widely, indicating that interhospital variability may not
be explained by access to an ID physician alone. Another possible explanation is that PICC placement
protocols may inform variation. For example, some hospitals may require ID physician approval prior
to PICC placement or as part of outpatient parenteral antimicrobial therapy planning, leading to more
appropriate device use.21 Also, there is likely to be some variation between hospitals with respect to
when ID physicians are consulted. Studies have shown wide variation in the use of ID physician
consultations and in the time to consultation in patients with bacteremia or transplant-related
infections.15,22 Similarly, physician consultation practices vary (eg, intensivists may be less likely to
consult an ID physician than other specialties).23 Thus, hospitals where ID physicians are engaged
early and often may provide more opportunities for ID physicians to inform and improve PICC use.
We also did not assess how ID physicians become involved in PICC approval or who within the ID
team becomes involved. For example, it is possible that some antibiotic stewardship programs
specifically include device assessment during antibiotic assessment. Similarly, ID-trained pharmacists
may also offer additional insight into device use when providing recommendations on appropriate
antibiotic therapy. Finally, patient characteristics may be associated with ID physician consultation
and approval. For example, clinicians may be less likely to consult an ID physician if patients have
multiple reasons for needing a PICC, beyond administration of intravenous antimicrobials. Patients
with multiple indications for PICCs may have more complicated diseases and, therefore, may be at
risk both for higher inappropriate PICC use and for more PICC-related complications. Thus, this group
potentially has the most to benefit from ID physician involvement in PICC decision-making.

Limitations and Strengths
Our study has limitations. First, we cannot say how approval from an ID physician was associated with
PICC use; however, anecdotal discussions with our sites suggest that ID physician engagement is
directly associated with PICC selection (eg, number of lumens) and device dwell times. Future
qualitative studies using ethnographic methods might be useful in this respect. Also, we cannot
assess whether ID physician consultation actually prevented PICC placement. Second, we
operationalized ID physician approval by looking for documentation in medical records. It is possible
that some PICCs may have been placed after verbal approval that was not documented; however,
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because this would bias our findings to the null (no effect due to misclassification), we would then
underestimate the association of ID physician approval with PICC appropriateness and outcomes.
Third, our study is observational and thus suggests an association rather than causation and may not
be generalizable beyond Michigan. Fourth, because patients were not randomized to PICC
placement, there is a potential for selection bias.
However, our study also has strengths, including robust statistical methods, inclusion of a large
group of diverse hospitals, and the use of a number of sensitivity analyses to verify our findings.
Second, we conducted a formal assessment of ID physician approval to ascertain the level of
engagement of these physicians, a practice that is difficult to assess without manual medical record
review. Third, we performed a rigorous assessment of appropriateness using validated criteria,
lending strength and importance to our findings. Fourth, all complications were reviewed using strict
definitions, ensuring that adverse events were appropriately recognized in a standardized fashion
across sites.
Our study has important implications and raises the question of whether hospitals should enact
policies that require ID physician approval of PICCs prior to placement, especially if the PICCs are
inserted for administration of intravenous antimicrobials. This approach would be similar to existing
policies requiring a nephrology physician’s approval for vascular catheter use in patients with CKD.
Furthermore, by reducing expensive PICC-related complications and improving patient outcomes, ID
physician approval prior to PICC placement could uniquely demonstrate the value of ID consultants
to health systems. Such an approach would be consistent with guidelines and studies that have
shown that ID physician involvement in outpatient parenteral antimicrobial therapy improves the
level of appropriateness of care and patient outcomes.24,25

Conclusions
This cohort study suggests that ID physician approval of PICC placement for administration of
intravenous antimicrobials is associated with a higher level of device appropriateness and fewer
complications. Policies that encourage ID physician engagement before placing PICCs for
administration of intravenous antimicrobials may improve patient safety.
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